MédiMabs understands that much time and effort is expended in the development of antibodies in research laboratories. However, although these agents are valuable and have a definite commercial potential within the same research community, only a small percentage of these are adequately exploited.

MédiMabs has consequently devised a royalty based compensation program to facilitate the licensing and the marketing of such antibodies, thus rendering the licensing process a rewarding one for academic institutions and research in general.

MédiMabs’ policy is one of direct dialogue with suppliers (Academic and industrial Technology Transfer Offices, researchers etc.) and customers (Academic and industrial researchers).

Please contact us for more information at 514-940-6227 or send us an email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it